Prof. Raffaele Mezzenga is a Full Professor at ETH Zürich's Department of Health Sciences and Technology and Head of the Institute of Food, Nutrition, and Health. He earned his master's from Perugia University (Italy) and a PhD in Polymer Physics from EPFL, followed by postdoctoral work at UC Santa Barbara. His career includes roles at the Nestlé Research Center and the University of Fribourg before joining ETH in 2009. His research focuses on self-assembly processes in polymers, biopolymers, and colloidal systems, with applications in environmental remediation, bioplastics, and biomedical materials. Key contributions include pioneering protein-based materials and advancing understanding of amyloid fibrils. Education: Master's, Materials Science & Engineering, Perugia University PhD, Polymer Physics, EPFL Research Interests: Self-assembly, biopolymers, amyloid materials, sustainable technologies, food colloids, and soft condensed matter. Awards: 2011 AOCS Award, 2017 APS Fellowship, and 2013 Biomacromolecules Young Investigator Award. Visiting Roles: Held visiting professorships at Aalto University, RMIT, Monash University, Nanyang Technological University, and others. Labs/Teams: Leads the Institute of Food, Nutrition, and Health at ETH, focusing on interdisciplinary research in food science and biomaterials. His work bridges fundamental science and applied innovation, addressing global challenges in sustainability and health through materials science. Recent projects include creating bioplastics from food waste, developing amyloid-based water purification systems, and advancing targeted drug delivery via lipidic mesophases.
Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Ruth Etzioni is an Affiliate Professor in the Biostatistics Program and Public Health Sciences Division at the Fred Hutchinson Cancer Center. She leads the Etzioni Lab, focusing on cancer screening, early detection, and overdiagnosis analysis. Her work integrates statistical modeling, epidemiology, and clinical research to address critical questions in prostate and breast cancer control. Dr. Etzioni holds the Rosalie & Harold Rea Brown Endowed Chair and has received a $7.4M NIH Outstanding Investigator Award. Education: PhD in Statistics (Carnegie Mellon University, 1990), MS in Statistics (Carnegie Mellon, 1987), BS in Mathematics (University of Cape Town, South Africa). Research interests emphasize biomarkers, clinical trials, and epidemiological methods. She leads the Biostatistics Core for the Pacific Northwest Prostate Cancer SPORE and participates in the Cancer Intervention and Surveillance Modeling Network (CISNET). Her lab develops models to evaluate screening policies, quantify overdiagnosis, and inform healthcare disparities reduction strategies. Key achievements include groundbreaking work on prostate cancer screening's harm-benefit tradeoffs and contributions to multi-cancer early detection (MCED) frameworks. Recent studies address racial disparities in prostate cancer outcomes, metastasis trends, and the clinical utility of novel diagnostics like PSMA PET imaging. Awards include the Brown Endowed Chair (2020), NCI OIA Award (2023), and recognition for advancing cancer data science. Her lab collaborates with institutions globally and mentors students in biostatistics and translational data science.
Prof. Abbas Samani is a Professor at the Department of Electrical and Computer Engineering and holds a joint appointment in the Department of Medical Biophysics at Western University . He is a core faculty member of the Biomedical Engineering Graduate Program and an Associate Scientist at Imaging Research Laboratories of Robarts Research Institute . His academic journey includes a Ph.D. from the University of Waterloo, an M.Sc. from the University of Tehran, and a B.Sc. from Amirkabir University of Technology. His research focuses on biological tissue computational modeling and its applications in medical imaging, intervention, and image analysis . He develops computer/image-assisted tools for minimally invasive disease diagnosis and therapy , targeting heart disease, cancer, and lung disease . Key projects include myocardium biomechanical modeling , handheld medical devices for breast cancer screening , and lung disease diagnostics via CT image segmentation . His recent publications emphasize ultrasound elastography , finite element modeling , and inverse problems in biomechanics , primarily in journals like IEEE Transactions on Computational Imaging and Translational Oncology . His work spans both computational modeling and medical device development . Selected Graduate Supervision : Ph.D. Candidates : Seyed Hassan Haddad, Elham Karami, Seyed Mohammad Hesabgar Graduated Ph.D. Students : Ali Sadeghi Naini, Seyed Reza Mousavi M.Sc. Students : Cristian Linte, Patrick Courtis, Joseph O'Hagan, Hatef Mehrabian, Hirad Karimi, Hosein Amooshahi, Seyed Mohammad Hesabgar, Nastaran Ghadarghadr, Shadi Shavakh, Ehsan Salamati, Ehsan Omidi Teaching Contributions : Graduate: BME9519B/CAMI9519B/ECE9202B/ECE9022B - Advanced Image Processing and Analysis , MBP9530A - Human Biomechanics and Biomedical Applications Undergraduate: ECE4438B - Advanced Image Processing and Analysis , ES1050 - Introductory Engineering Design and Innovation Studio , MBP3330F - Human Biomechanics and Biomedical Applications Research Affiliations : Robarts Research Institute - Associate Scientist at Imaging Research Laboratories Western University - Core Faculty, Biomedical Engineering Graduate Program
John E. Moses is a Professor at Cold Spring Harbor Laboratory (CSHL), where he leads the Moses Laboratory and serves as Faculty Head of the Mass Spectrometry Shared Resource for the Cancer Center. He is also a Cancer Center Member focusing on developing chemical tools for biological discovery, particularly in cancer research. Dr. Moses earned his D.Phil. in Synthetic Organic Chemistry from the University of Oxford in 2004. His academic journey includes positions as Professor of Organic Chemistry at La Trobe University (2017-2020), Level 6 Future Fellow at the Australian Research Council (2017-2021), and Reader & Associate Professor in Organic Chemistry at the University of Nottingham (2007-2017). Moses' research focuses on click chemistry, a powerful discovery method that uses robust chemical reactions to synthesize functional molecules. His lab specializes in developing and exploiting bond-forming click reactions for rapid synthesis of small functional molecules, including cancer drugs and chemical probes. They apply these molecular tools in multidisciplinary projects spanning biology and chemistry. His recent work has led to significant advances in click chemistry methodologies, including Diversity Oriented Clicking (DOC) and Phosphorus Fluoride Exchange (PFEx). These approaches have enabled the discovery of new cancer therapeutics and antibiotics effective against multidrug-resistant bacteria like MRSA. Dr. Moses has received numerous honors including the 2021 Organic Division Horizon Prize: Robert Robinson Award in Synthetic Organic Chemistry, Fellow of the Royal Society of Chemistry (2015), Thieme Chemistry Award (2011), and UK & ROI Lilly Award for Excellence in Organic Chemistry (2011). Through his work at CSHL, Moses mentors students and postdoctoral researchers while collaborating with biologists to develop Chemistry For Biology. His lab's innovative approaches have been supported by multiple grants, including those from the National Cancer Institute. The Moses Laboratory is at the forefront of click chemistry research, developing new methodologies while applying them to solve critical problems in cancer biology and antibiotic resistance.
Ovijit Chaudhuri is an Associate Professor of Mechanical Engineering at Stanford University, with a courtesy appointment in Bioengineering. He leads research at the interface of mechanics and biology, focusing on how cellular and extracellular mechanical properties influence biological processes like cancer progression and tissue formation. His work employs advanced tools such as atomic force microscopy and 3D cell culture systems. Education: Ph.D., University of California, Berkeley/San Francisco (Bioengineering, 2009) B.S., University of California, Berkeley (Engineering Physics, 2003) Postdoctoral Fellow, Harvard University (Biomaterials, 2013) Research Interests: His lab explores molecular mechanisms behind cellular mechanics, extracellular matrix dynamics, and how mechanical cues regulate cell behavior. Key areas include cancer metastasis, mechanotransduction, and engineered biomaterials for 3D cell culture. Publications Trends: Recent work emphasizes viscoelastic hydrogels, matrix mechanics in cancer progression, and mechanistic insights into cell migration. Over 50 publications since 2015 highlight interdisciplinary approaches in biomaterials and mechanobiology. Awards: Not explicitly listed in provided materials. Advising & Labs: No specific advisee names listed, but his lab focuses on collaborative projects in mechano-biology. Active in developing biomaterial systems for drug discovery and tissue engineering applications. Labs/Teams: Leads the Chaudhuri Lab at Stanford, which integrates engineering principles with biological systems to address complex disease mechanisms and therapeutic strategies.
Maciej A Mazurowski is an Associate Professor at Duke University School of Medicine, with dual appointments in the Department of Biostatistics & Bioinformatics and Radiology. He is also affiliated with the Department of Electrical and Computer Engineering and is a member of the Duke Cancer Institute. His research focuses on applying machine learning to medical imaging for improved diagnosis and treatment. Ph.D. in Computer Science from the University of Louisville (2008) Dr. Mazurowski's research emphasizes medical imaging , machine learning , and computer vision applications in radiology. His work includes automated segmentation , domain adaptation , prognostic modeling , and foundation models for MRI/CT analysis. His recent publications highlight trends in universal segmentation models (SegmentAnyBone, SegmentAnyMuscle), foundation models for MRI (MRI-CORE), and AI-driven diagnostic tools for breast cancer, glioblastoma, and thyroid nodules. Key challenges addressed include domain generalization , image harmonization , and ethical considerations in clinical AI. Incubation Award for innovative research commercialization Dr. Mazurowski has secured significant research funding from agencies including the National Institutes of Health , National Institute of Biomedical Imaging and Bioengineering , and American Roentgen Ray Society . His work spans CT segmentation , MRI analysis , and AI-based quality assessment across multiple imaging modalities.
Dana Pe'er is a Professor and Chair of the Computational and Systems Biology Program at the Sloan Kettering Institute (SKI) of Memorial Sloan Kettering Cancer Center. She is also an Investigator of the Howard Hughes Medical Institute and holds the Alan and Sandra Gerry Endowed Chair. Dr. Pe'er leads an interdisciplinary research group that combines advanced genomics approaches with machine learning to address fundamental questions in biomedical science, with particular focus on cancer biology, developmental biology, and immunology. Dr. Pe'er earned her PhD from Hebrew University in Jerusalem, Israel. Her academic journey includes a postdoctoral fellowship with George Church at Harvard Medical School. Before joining Memorial Sloan Kettering Cancer Center in 2016, she held faculty positions at Columbia University. Dr. Pe'er's research focuses on understanding cellular plasticity, the consequences of intra-tumor heterogeneity, cancer evolution and metastasis, and the mechanisms by which regulatory circuits go awry in disease. Her lab combines single-cell and spatial profiling technologies with machine learning approaches to investigate gene regulation, cellular plasticity, and cell-cell communication in the contexts of cancer, immunity, and development. They are particularly interested in how organisms develop from a single cell to generate diverse cell types, how epigenetic control rewires during development, and how cells communicate to execute multicellular responses. Analysis of Dr. Pe'er's recent publications reveals a strong focus on developing computational methods for single-cell and spatial genomics data analysis. Her work spans cancer types including pancreatic, prostate, colorectal, and breast cancer, with emphasis on tumor heterogeneity, metastasis mechanisms, and cellular plasticity. A significant portion of her research involves creating novel algorithms and tools like CellRank, REUNION, and SEACells that enable researchers to extract meaningful biological insights from complex genomic datasets. 2023 Class of 2023 Inductee - American Academy of Cancer Research (AACR) Academy 2023 Innovator Award - International Society for Computational Biology (ISCB) 2021 Fellow - International Society for Computational Biology (ISCB) Howard Hughes Medical Institute Investigator (2021) 2019 Ernst W. Bertner Memorial Award - University of Texas MD Anderson Cancer Center 2016 Lenfest Distinguished Faculty Award - Columbia University 2014 Director's Pioneer Award - National Institutes of Health 2014 Overton Prize - International Society for Computational Biology (ISCB) Dr. Pe'er is known for her dedicated mentorship approach, describing herself as "a mama bear" who cares deeply about her trainees while expecting independence, innovation, and hard work. She mentors numerous PhD students and postdocs in her lab. Her HHMI Investigator award provides approximately $9 million over seven years, enabling ambitious research directions. She also collaborates extensively with the Single-cell Analytics and Innovation Lab (SAIL) at MSK to generate new data from emerging technologies, working closely with wet-lab collaborators at MSK and beyond to apply computational methods to cutting-edge datasets across multiple disease areas. The Pe'er Lab is an interdisciplinary group of computational biologists with diverse backgrounds ranging from pure mathematics to clinical medicine. They work closely with wet-lab collaborators to apply their computational methods to cutting-edge datasets across cancer, immunology, and developmental biology. The lab is described as open, supportive, collaborative, and fun, with access to world-class facilities at the Sloan Kettering Institute. Dr. Pe'er's work continues to push the boundaries of computational biology and cancer research, with the ultimate goal of developing more effective, personalized therapies for cancer patients.
Jens S. Andersen is a Professor in the Department of Biochemistry and Molecular Biology at the University of Southern Denmark, where he leads research in Biomedical Mass Spectrometry and Systems Biology. His work is centered on the development and application of quantitative mass spectrometry and microscopy-based proteomics to study human cell biology, particularly the structure and function of organelles such as centrosomes, cilia, autophagosomes, and mitochondria. His research focuses on determining the protein composition and dynamic properties of cellular organelles, the roles of specific protein groups, and their contributions to biological processes and diseases. He investigates cell signaling mediated by post-translational modifications, especially within the DNA damage response, autophagy, and immune systems. His lab, the Jens S. Andersen Lab, is part of the Research Section of Biomedical Mass Spectrometry. The analysis of his recent publications reveals a strong interdisciplinary trend combining proteomics, structural biology, and cell signaling. His work spans cilia biology, RNA metabolism, DNA repair, and cancer mechanisms, with frequent use of advanced techniques like mass spectrometry, CRISPR, and live-cell imaging. The integration of systems biology approaches is evident across his research outputs. Professor, Department of Biochemistry and Molecular Biology, University of Southern Denmark Head of Research, Biomedical Mass Spectrometry and Systems Biology Principal Investigator, Jens S. Andersen Lab ORCID: 0000-0002-6091-140X While no specific scientific awards are mentioned in the provided texts, his extensive publication record in high-impact journals such as Science , Nature Communications , Molecular Cell , and EMBO Journal reflects significant scholarly contributions. He has supervised research projects and collaborated widely across Europe, though specific names of students are not listed. His research is supported by multiple ongoing projects, reflecting sustained funding and academic leadership. The Jens S. Andersen Lab operates at the intersection of proteomics and cell biology, contributing to fundamental understanding of organelle dynamics and disease mechanisms. The lab's work is highly collaborative, involving partnerships with groups in structural biology, RNA research, and cancer biology.
Dr. Karen Anderson is a Professor at Arizona State University (ASU), affiliated with the School of Life Sciences, the Biodesign Center for Personalized Diagnostics, and the College of Health Solutions. Her research focuses on tumor biology and immune system interactions in cancer, particularly developing biomarkers for early detection of cancers like breast, ovarian, pancreatic, and HPV-related cancers. She employs molecular techniques such as protein arrays, next-gen sequencing, and functional genomics to identify therapeutic targets and vaccine candidates. Education: Ph.D. in Microbiology and Immunology (Duke University), M.D. from Duke University School of Medicine, and B.A. in Chemistry (University of Virginia). Research interests include cancer immunotherapy, autoantibody profiling, and translational applications of proteomics. Key achievements include pioneering autoantibody-based biomarker assays and investigating HPV serology in head and neck cancers. Awards include the Health Care Heroes Award and recognition as one of Arizona's Most Influential Women. Teaching responsibilities include courses on research techniques and honors thesis supervision. Grants span biomarker validation, cancer genomics, and point-of-care diagnostics. Active in professional service, including roles in grant review panels and public health initiatives.
Hsueh-Chia Chang is the Bayer Professor of Chemical Engineering in the Department of Chemical and Biomolecular Engineering at the University of Notre Dame's College of Engineering. He also holds a concurrent faculty position in the Department of Aerospace and Mechanical Engineering. As Principal Investigator of the Chang Lab, he leads cutting-edge research in microfluidic and nanofluidic technologies for biomedical applications. Prof. Chang received his B.S. in Chemical Engineering from Caltech in 1976, followed by M.S. and Ph.D. degrees in Chemical Engineering from Princeton University in 1977 and 1980, respectively. His academic journey has established him as a leader in the field of microfluidics and biosensing technologies. Chang's research focuses on developing low-cost liquid biopsy nanotechnologies for cancer screening and therapy management. His lab specializes in microfluidic and nanofluidic research coupled with electrokinetics, optics, plasmonics and acoustics for biosensing applications. Key research areas include Electrokinetics & Biosensing, Optics & Plasmonics, Nanoelectrokinetics, and Droplet Microfluidics. The Chang Lab has developed innovative platforms that can isolate and sort tumor cells, exosomes, microvesicles, lipoproteins, and stress granules from blood samples, then lyse these structures to release RNA/protein biomarkers for detection and quantification. His recent publications reveal a strong focus on extracellular vesicle diagnostics, cancer biomarker detection, and point-of-care diagnostic technologies. The research spans multiple disciplines including oncology, cardiology, and neurology, with applications for pancreatic, liver, breast, ovarian, and lung cancers as well as myocardial infarction diagnosis. Fellow of American Institute of Medical and Biological Engineering (2025) Provost Research Achievement Award, Notre Dame (2024) Fellow of the National Academy of Inventors (2020) Lifetime Achievement Award, American Electrophoresis Society (2019) Fellow of the American Physical Society (1997) Presidential Young Investigator Award, NSF (1985) Prof. Chang has advised over 50 PhD students and postdocs who have gone on to prominent positions in academia and industry. His lab has secured significant funding and has commercialized several technologies through startups like Aopia Biosciences, which launched NanoEx at ISEV 2024. The Chang Lab maintains active collaborations with medical researchers for validating their diagnostic platforms against various cancers and cardiac conditions.
Dr. Fnu Aakash serves as Interim Director of Hematopathology and Assistant Professor in the Department of Pathology at the University of Texas Medical Branch. His research focuses on hematopathology, oncology diagnostics, and clinical significance of neoplastic disorders. With an h-index of 55, Aakash has contributed significantly to cancer classification systems through publications in Modern Pathology and American Journal of Surgical Pathology. His recent work includes developing international consensus guidelines for myelodysplastic neoplasms and characterizing non-neoplastic changes associated with breast implants. Research collaborations span multiple institutions including MD Anderson Cancer Center, with specialization in malignant hematology and lymphoma diagnostics.
Ping He is a Professor in the Department of Molecular, Cellular, and Developmental Biology (MCDB) at the University of Michigan in Ann Arbor. His research focuses on plant immunity mechanisms, particularly using Arabidopsis as a model system to study pathogen defense activation, signaling pathways, and the interplay between immunity and environmental stress responses. He also leads the Molecular, Plant-Microbe Interaction Laboratory, applying interdisciplinary approaches (genetics, biochemistry, cellular biology) to enhance crop resilience through foundational plant science discoveries. His work bridges plant biology and computational biology, with recent contributions to AI-driven medical imaging applications such as bladder cancer treatment response assessment, lung cancer early detection, and breast tomosynthesis denoising. These efforts emphasize integrating machine learning into clinical workflows and establishing best practices for AI in healthcare. Research Highlights: Plant immunity signaling and environmental stress crosstalk Radiomics and deep learning for cancer diagnosis/prognosis AI model validation and multi-institutional clinical trials Medical imaging artifact correction (e.g., motion blur, noise) Publications emphasize AI applications in oncology imaging, radiologist decision support systems, and multimodal data fusion. He has contributed to AAPM task group guidelines for AI in computer-aided diagnosis and advocates for rigorous quality assurance frameworks in medical AI deployment.
Elisabeth Prince is an Assistant Professor at the University of Waterloo, specializing in polymer chemistry and biomaterials. Her research focuses on developing advanced materials for biomedical applications, sustainable materials, and microfluidic technologies. Key areas include conductive hydrogels, cleavable polymers for recyclability, and biomimetic systems for drug delivery and cancer therapy. Her work bridges disciplines such as materials science, nanotechnology, and biomedical engineering. Recent studies involve applications in strain-stiffening hydrogels, filamentous aerogels for electromagnetic shielding, and microfluidic platforms for organoid production. These innovations aim to address challenges in regenerative medicine, environmental sustainability, and personalized cancer treatments. No scientific awards are listed in the provided materials. Research activities include collaborations on 3D-printed microfluidic devices and nanofibrillar hydrogels mimicking biological systems. No advising relationships or grants are explicitly mentioned in the text.
Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute , Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery. Education & Training PhD in Chemistry – University of Toronto (2013) HBSc in Chemistry (Honours) – University of British Columbia (2008) CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016) Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021) Research Focus Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology , aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3 . The group employs cellular thermal shift assays , isothermal ligand-induced resolubilization (ILIRA) , and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases . Funding & Collaborations His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement. Equity, Diversity & Inclusion Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.
